» Articles » PMID: 35877583

Low Prevalence of Cardiomyopathy in Patients with Mitochondrial Disease and Neurological Manifestations

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with mitochondrial diseases can develop cardiomyopathy but with variable expressivity and penetrance. Our prospective study enrolled and evaluated a cohort of 53 patients diagnosed with chronic progressive ophthalmoplegia (CPEO, = 34), Kearns-Sayre syndrome (KSS, = 3), neuropathy ataxia and retinitis pigmentosa (NARP, = 1), myoclonic epilepsy with ragged red fibers (MERRF, = 1), Harel-Yoon Syndrome (HYS, = 1) and 13 patients with undefined mitochondrial diseases, presenting primarily with neurological symptoms. Over a 4-year period, six patients in our study cohort were diagnosed with heart disease (11.3%), with only three patients having defined cardiomyopathy (5.7%). Cardiomyopathy was present in a 21-year-old patient with HYS and two CPEO patients having mild cardiomyopathy at an older age. Two CPEO patients had congenital heart disease, and a third CPEO had LV hypertrophy secondary to hypertension. In three patients, traditional risk factors for heart disease, including dyslipidemia, hypertension, and respiratory disease, were present. The majority of our adult cohort of patients have normal cardiac investigations with a median left ventricular (LV) ejection fraction of 59.0%, indexed LV mass of 67.0 g/m, and normal diastolic and valvular function at baseline. A 12-lead electrocardiogram showed normal cardiac conduction across the study cohort. Importantly, follow-up assessments showed consistent cardiac structure and function. Our study shows a low prevalence of cardiomyopathy and highlights the breadth of phenotypic variability in patients with mitochondrial disorders. The presence of cardiovascular risk factors and aging are important comorbidities in our cohort.

Citing Articles

Myoclonic Epilepsy With Ragged Red Fiber Cardiomyopathy: A Case Report and Brief Review of Literature.

Levra A, Amata F Cureus. 2024; 16(8):e66745.

PMID: 39268300 PMC: 11391248. DOI: 10.7759/cureus.66745.


Advances in Neurological Diseases and Stroke.

Venketasubramanian N J Cardiovasc Dev Dis. 2023; 10(2).

PMID: 36826562 PMC: 9966626. DOI: 10.3390/jcdd10020066.

References
1.
Bittles A . Evidence for and against the causal involvement of mitochondrial DNA mutation in mammalian ageing. Mutat Res. 1992; 275(3-6):217-25. DOI: 10.1016/0921-8734(92)90025-k. View

2.
Pankuweit S, Richter A . Mitochondrial disorders with cardiac dysfunction: an under-reported aetiology with phenotypic heterogeneity. Eur Heart J. 2015; 36(42):2894-7. DOI: 10.1093/eurheartj/ehv429. View

3.
Quadir A, Pontifex C, Robertson H, Labos C, Pfeffer G . Systematic review and meta-analysis of cardiac involvement in mitochondrial myopathy. Neurol Genet. 2019; 5(4):e339. PMC: 6659349. DOI: 10.1212/NXG.0000000000000339. View

4.
Kabunga P, Lau A, Phan K, Puranik R, Liang C, Davis R . Systematic review of cardiac electrical disease in Kearns-Sayre syndrome and mitochondrial cytopathy. Int J Cardiol. 2014; 181:303-10. DOI: 10.1016/j.ijcard.2014.12.038. View

5.
Holmgren D, Wahlander H, Eriksson B, Oldfors A, Holme E, Tulinius M . Cardiomyopathy in children with mitochondrial disease; clinical course and cardiological findings. Eur Heart J. 2003; 24(3):280-8. DOI: 10.1016/s0195-668x(02)00387-1. View